Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Wulff Group Plc’s Interim Report for January 1 – September 30, 2023

INTERIM REPORT | OCTOBER 23, 2023 AT 9.30 A.M. This is a summary of Wulff Group Plc’s Interim Report January 1–September 30, 2023. The complete report is attached to this stock exchange release as a pdf-file. The report is also available at the website www.wulff.fi. The third quarter fell short of expectations – operational programme will improve profitability 1.7.–30.9.2023 BRIEFLY · Net sales totalled EUR 21.2 million (24.0), decreased by 11.6% · EBITDA was EUR 0.8 million (1.7) and comparable EBITDA was EUR 1.1 million (1.7) · Operating profit (EBIT) was EUR 0.3

Catena Media announces share buybacks executed from 16 to 20 October 2023

Catena Media plc (LEI code: 549300609A73DL5C5Z86) repurchased 75,000 of its own ordinary shares (ISIN code: MT0001000109) from 16 to 20 October 2023 as part of its share buyback programme. The buyback programme was authorised by shareholders at an extraordinary general meeting on 12 July 2023 and initiated and announced by the board of directors on 17 July 2023. The programme is being carried out in accordance with the EU Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Its purpose is to deliver

Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023

Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Stephane Dalle, the top recruiting investigator of the ATLAS-IT-05 study, will give a poster presentation today at the ESMO 2023 Congress.ATLAS-IT-05 is a Phase II open label clinical trial with LTX-315 in combination with Keytruda® (pembrolizumab) in stage III-IV melanoma patients refractory to treatment with PD-1 / PD-L1 inhibitors.   The poster presents early preliminary clinical data from 20 patients (14 patients for efficacy)

Bulten AB nomination committee for 2024 AGM appointed

The Bulten Annual General Meeting will be held in Gothenburg, Sweden on Thursday April 25, 2024. Nomination committee members for the meeting have now been appointed.The nomination committee shall, according to the AGM’s decision, consist of four members: a representative for each of the three major shareholders on the last banking day in September who wish to appoint a member to the nomination committee, and the Chairman of the Board. The three major shareholders refer to those registered and ownership-grouped by Euroclear Sweden AB as of the last banking day in September. If any of the

AFRY awarded owner’s engineering services for a new waste-to-energy project in Malaysia

Worldwide PMC Sdn. Bhd. (WPMC) has awarded AFRY a contract to provide owner’s engineering services for a waste-to-energy project in Kuala Selangor, Malaysia, that will enable more efficient and sustainable municipal waste management.State-of-the-art waste-to-energy (WtE) facilities are an essential component for accelerating the transition to a sustainable future, as they are designed to recover the value of the waste that remains after reusing and recycling, and convert it into energy. The new plant in Malaysia will significantly reduce the amount of waste going to landfills and

Concentric AB wins first important order for next generation Electro Hydraulic Steering (EHS) with leading electric bus OEM in Europe

Concentric AB is proud to announce the win of a significant order of our next-generation Electro Hydraulic Steering (EHS) pump from a leading European electric bus OEM. This order is worth 7 MSEK and will be supplied from Q4 this year, into Q1 of 2024. Based on our strategic relationship with the customer, we are confident that this order will be the foundation for a long-term supply agreement. The new generation of EHS units are fitted with Concentric’s state of the art Internal Gear Pump (IGP), which is optimised to meet low noise steering system requirements, in one compact design.

Getinge Interim Report July - September 2023: Higher sales, gradually strengthened margins and stable cash flows

“Getinge’s sales rose organically by 5.7% in the quarter,” says Mattias Perjos, President & CEO at Getinge. “Most of the operations in Acute Care Therapies performed positively. Sales in Life Science were unchanged and Surgical Workflows grew in all product categories and regions. The order intake declined organically by a total of 1.9% in the quarter, which was exclusively linked to Acute Care Therapies.”The Group’s margins and cash flow were positively impacted sequentially by higher deliveries of consumables, mainly in Cardiac Assist. However, continuing low demand in products for the

Interim report January - September 2023

Good order intake Quarter 3, 2023   · Orders received amounted to SEK 1,488m (1,294), equivalent to currency neutral growth of 11.0 percent compared with the same period last year. · Net sales amounted to SEK 1,574m (1,398), equivalent to currency neutral growth of 7.7 percent compared with the same period last year. · Adjusted EBITA was SEK 175.4m (165.3), giving an adjusted EBITA margin of 11.1 percent (11.8). · Operating profit amounted to SEK 148.0m (138.0), corresponding to an operating margin of 9.4 percent (9.9). · Net profit was SEK 85.4m (92.6). · Earnings

Nitro Games Oyj: Interim Report January – September 2023

THE INTERIM PERIOD JANUARY – SEPTEMBER 2023 · Revenues (Jan – Sep) 5,946.9 KEUR (4,935.0 KEUR in the corresponding period 2022). · EBITDA: -2,502.8 KEUR (-2,444.4 KEUR). · EBIT: -3,377.6 KEUR (-3,051.9 KEUR). · Net result: -3,585.5 KEUR (-3,094.1 KEUR). · Earnings per share (EPS) -0.24 (-0.24). · Cash and cash equivalents: 1,809.2 KEUR (30 September 2023) and 1,256.3 KEUR of short-term receivables (30 September 2023). (All figures are presented in accordance with IFRS and, unless otherwise stated, the comparison figures in brackets refer to the corresponding period in

Peab builds rental apartments in Malmö

Peab has been commissioned to build rental apartments in Malmö. The customer is MKB Fastighets AB and the contract is worth SEK 408 million.The new apartments will be built in Kirseberg in Malmö. The project consists of three buildings with a varying height of six to eight stories. All in all Peab will build 264 apartments and six other premises. “We’re proud to be able to contribute together with MKB to more homes for Malmö residents. This is a good example of our locally produced community building,” says Peter Lindstedt, Region Manager Peab. The project is a turnkey contract in

The SESAR investigator-initiated trial completes patient enrollment

Sedana Medical AB (publ) today announces that the enrollment of the planned 700 patients in the SESAR trial has been completed. The trial Sevoflurane for Sedation in Acute Respiratory Distress Syndrome: A Multicenter Prospective Randomized Trial (SESAR) is an investigator-initiated trial (IIT) that is supported in part by Sedana Medical and by the French Ministry of Health.The SESAR trial, comparing sevoflurane via the Sedaconda ACD with intravenous propofol for up to 7 days is led by professor Matthieu Jabaudon and his team from Clermont Ferrand, France. The patient population consists of

Fredrik Meuller is appointed new President and CEO of Inwido

The board of Inwido has appointed Fredrik Meuller as the new President and CEO. He will take office after agreement but no later than 1 May, 2024."I’m proud and happy to be able to announce Fredrik Meuller as the new President and CEO", says Inwido's chairman of the board Per Bertland. "He is a competent leader and in his position as CEO of Nord-Lock Group he’s shown that he has a deep understanding of how to create both organic and acquisition-driven growth in an international business. I am convinced that he will be able to further develop what Inwido has built up and lead the Group to

AMSC ASA: Agreement on participation in Solstad Offshore’s refinancing transaction

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Lysaker, October 23, 2023 – Reference is made to the stock exchange announcement by Solstad Offshore ASA (“SOFF”) today that Solstad Shipholding AS (“Solstad”) has reached an agreement with Aker ASA (via its wholly owned subsidiary Aker Capital AS,

Aker ASA: Aker Enables Refinancing of Solstad Offshore

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Fornebu, October 23, 2023 – Reference is made to the stock exchange notice by Solstad Offshore ASA (“SOFF”) today regarding the refinancing of Solstad Shipholding AS (“Solstad”). Aker ASA (via its wholly owned subsidiary Aker Capital AS, hereinafter “

Refinancing of Solstad Offshore

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Skudeneshavn, October 23, 2023 – Solstad Offshore ASA ("SOFF" and, together with its subsidiaries, the "Solstad Group") is pleased to announce that its subsidiary Solstad Shipholding AS (“Solstad”) has reached an agreement with Aker ASA (via its

Michael Green appointed new President and Group Chief Executive Officer

Michael Green was today appointed President and Group Chief Executive Officer of Svenska Handelsbanken AB (publ). He is currently General Manager of the Bank’s operations in Sweden.Michael Green takes up his new position on 1 January 2024 and will succeed the present CEO, Carina Åkerström.“The Board’s process has been very thorough and comprehensive. We have also engaged external expertise to evaluate the various candidates, both external and internal, but in the end Michael was the natural choice. Extremely competent, with long, extensive experience of nearly 30 years at the Bank – at

ZWIPE AS – Q3 2023 Operational Update

OSLO, NORWAY – 23 October 2023 – During the third quarter, Zwipe continued to demonstrate progress and saw strong interest from partners in bringing biometric payment and access control cards to markets globally.  Significant events during the period · Beautiful Card Corporation (“BCC”) receives LoA from Mastercard to deploy Zwipe Pay biometric payment cards, making it the second Zwipe smart card manufacturer (“SCM”) to receive certification from both major payment schemes. · Zwipe partners with OLOID to offer biometric access cards globally. · Zwipe partners with AWT to

Wihlborgs wins new construction assignment from Malmö University

Wihlborgs has won the assignment from Malmö University to, in consultation with the university and the City of Malmö, design and construct buildings at the Malmö Amphitrite 1 property, to be leased in the future by the university.Wihlborgs and Malmö University have signed an implementation agreement for the parallel execution of architectural assignments, design, construction and, finally, letting to Malmö University at the Malmö Amphitrite 1 property, which is centrally located by the university’s statement Niagara building. The building is currently owned by the City of Malmö. A

New Data on BerGenBio’s Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

BERGEN, Norway, October 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer (NSCLC) were presented during the European Society of Clinical Oncologists (ESMO) Annual Meeting 2023.   The poster presentation is now available on BerGenBio’s website under →Pipeline→Scientific Publications.   In addition, on October 21st, Dr.  Oddbjorn

Shape Robotics awarded large order in the Republic of Moldova

Company announcement no. 35-23Copenhagen, Oct 23, 2023 Shape Robotics is awarded an order in level of DKK 5 million. The order contains the delivery of seven STEAM Labs to high schools in Chisinau. The order will be delivered in December 2023. In June 2023, Shape Robotics opened a subsidiary in the Republic of Moldova, executing the growth strategy the company announced in the spring of 2023. The announced order is awarded after several smaller orders to public and private schools throughout the autumn of 2023. EU and World Bank build momentum behind Moldova's tech sector As

Nanoform grant Global STARMAP[®] AI License to AstraZeneca

Press release Nanoform Finland Plc October 23, 2023 08:10 Finnish time / 07:10 Swedish time Nanoform grant Global STARMAP[®] AI License to AstraZeneca Helsinki, Finland – Nanoform Finland Plc. (Nanoform), an innovative nanoparticle medicine-enabling company today announced that it has granted AstraZeneca Plc a global online STARMAP[®] license. STARMAP[®] is a digital AI version of the CESS[®] technology that enables in-silico experiments to determine which molecules should be nanoformed. The license will enable AstraZeneca to screen molecules from drug discovery through to

Ratos AB: Strong cash flows, reduced leverage and 20% increase in EBITA

Q3 2023 · Adjusted EBITA amounted to SEK 517m (432) · Operating profit amounted to SEK 481m (406) · Profit for the period amounted to SEK 287m (283) and was impacted by net financial items of SEK -172m (-63) · Diluted earnings per share amounted to SEK 0.57 (0.61) · Cash flow from operating activities amounted to SEK 862m (736) January-September 2023 · Adjusted EBITA amounted to SEK 1,918m (1,648) · Operating profit amounted to SEK 1,804m (1,336) · Profit for the period amounted to SEK 1,026m (834) and was impacted by net financial items of SEK -573m (-267)

There are no items matching the current filter
There are no more items matching the current filter
Back to top